Prostate & Urologic Cancer Center Blog

Spencer Hauck, Ph.D., and Lingfan Xu, Ph.D., both postdoctoral fellows in Dr. Jiaoti Huang’s research laboratory, have been awarded the Department of Defense Prostate Cancer Research Program’s 2020 Early Investigator Research Award.

The U.S. Food and Drug Administration (FDA) recently approved BAVENCIO®(avelumab) for the maintenance treatment of patients with locally advanced or metastatic bladder cancer that has not progressed with first-line platinum-containing chemotherapy.

Christopher Hoimes, DO, PhD, joined the genitourinary oncology program at Duke Cancer Institute as Associate Professor of Medicine where he will serve as clinical investigator with a focus on GU cancers, experimental therapeutics, and early phase trials.  

Erectile dysfunction (ED) is the most common side effect of prostate radiotherapy (RT), but reported rates over time and across modalities have varied widely.

“I’m a father today because of my amazing Duke family,” explained Hendrix. “From the bottom of my heart, thank you. Every step of the way, the care team at Duke went above and beyond. I can’t even imagine what our lives would be like without the care I received from Drs. Robertson and Armstrong, and my family is eternally grateful.”

A multi-institutional group of clinical researchers, including Duke Cancer Institute’s Andrew Armstrong, MD, McS, FACP, published a new report this month in the European Urology journal that describes results of patient-reported outcomes (PROs) on the ARCHES study.

Due to concern for the health and welfare of participants, and in order to comply with official North Carolina Stay-At-Home orders, the BCAN 5K Walk/Run will be a Virtual Event held on Saturday, May 2.

Landon Brown, medical oncology fellow at Duke Cancer Institute, has been selected to receive a 2020 Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) Merit Award.

‘HeroesResearch.org’ will enroll front-line workers to answer crucial questions about coronavirus

The study is the first cardiovascular outcomes trial to compare two different types of cancer treatment.

Men should provide their doctors a family history of cancer that includes female relatives.

10 DCI Center for Prostate & Urologic Cancers abstracts accepted for presentation at the 2020 GU ASCO.